-
公开(公告)号：US20240201170A1
公开(公告)日：2024-06-20
申请号：US18555348
申请日：2022-04-18
CPC分类号： G01N33/5011 , C12N5/0693 , G01N33/5082 , C12N2500/50 , C12N2501/727 , C12N2533/50 , C12N2533/80 , C12N2537/10 , G01N2500/10
摘要： The present invention relates to the maintenance and/or culture of tissue slices in vitro or ex vivo. In particular, the present invention relates to a method for the maintenance and/or culture of tissue slices using hydrogels. In one embodiment, the hydrogel is a semi-synthetic hydrogel comprising thiolated hyaluronan with acrylated peptides comprising KGGGPQGIWGQGK (SEQ ID NO: 1) that are degradable by matrix metalloproteinases. In particular, the present invention provides a platform suitable for downstream analysis such as real-time imaging, other real-time study of the tissue in culture and testing of a therapeutic agent or a potential therapeutic agent.
-
公开(公告)号：US11970680B2
公开(公告)日：2024-04-30
申请号：US16089220
申请日：2017-03-30
申请人： EMULATE, INC.
发明人： Geraldine A. Hamilton , Norman Wen , Catherine Karalis , Antonio Varone , Daniel Levner , Riccardo Barrile
CPC分类号： C12M23/16 , C12M25/02 , C12N5/0693 , G01N33/5011 , G01N33/5017
摘要： The invention generally relates to a microfluidic platforms or “chips” for testing and understanding cancer, and, more specifically, for understanding the factors that contribute to cancer invading tissues and causing metastases. Tumor cells are grown on microfluidic devices with other non-cancerous tissues under conditions that simulate tumor invasion. The interaction with immune cells can be tested to inhibit this activity by linking a cancer chip to a lymph chip.
-
公开(公告)号：US20240131130A1
公开(公告)日：2024-04-25
申请号：US18277897
申请日：2022-02-17
发明人： Anahid Jewett
CPC分类号： A61K39/0011 , C12N5/0693 , C12N15/86 , A61K2039/5152 , A61K2039/572 , C12N2529/00 , C12N2710/16143
摘要： The present invention is based, in part, on cancer vaccine compositions or pharmaceutical compositions comprising cancer cells, monocytes, and/or osteoclasts that activate NK cells, and methods for using same to prevent and/or treat diseases such as cancer.
-
公开(公告)号：US11957729B2
公开(公告)日：2024-04-16
申请号：US16510442
申请日：2019-07-12
发明人： Hans Georg Rammensee , Stefan Stevanovic , Cecile Gouttefangeas , Toni Weinschenk , Peter Lewandrowski
IPC分类号： A61K39/00 , A61K38/10 , C07K7/08 , C07K14/47 , C07K14/705 , C07K16/18 , C07H21/00 , C12N5/0783 , C12N5/09 , C12N15/10 , C12N15/86
CPC分类号： A61K38/10 , A61K39/00115 , C07K7/08 , C07K14/4747 , C07K14/4748 , C07K14/7056 , C07K16/18 , C07H21/00 , C12N15/10 , C12N15/86
摘要： The present invention relates to peptides, nucleic acids, and cells for use in the immunotherapy of cancer. The present invention furthermore relates to survivin-derived tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention specifically relates to three novel peptide sequences and variants thereof derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
公开(公告)号：US11952632B2
公开(公告)日：2024-04-09
申请号：US16959557
申请日：2019-01-06
申请人： NUCLEIX LTD.
发明人： Danny Frumkin , Adam Wasserstrom , Revital Knirsh
IPC分类号： C12P19/34 , C12N5/09 , C12N15/10 , C12N15/66 , C12Q1/6827 , C12Q1/6886 , G01N33/574
CPC分类号： C12Q1/6886 , C12N5/0693 , C12N15/1089 , C12N15/66 , C12Q1/6827 , G01N33/574 , C12Q2537/165 , C12Q2565/40
摘要： Methods and kits for detection of cancer-related mutations in a DNA sample using enzymatic restriction and real-time PCR. A DNA sample is subjected to digestion with a restriction endonuclease to obtain restriction endonuclease-treated DNA, followed by co-amplification of a restriction locus comprising a cancer mutation site and a control locus. A ratio of signal intensities of the amplification products of the restriction locus and the control locus is used to detect the cancer-related mutation.
-
26.发明公开公开(公告)号：US20240108762A1
公开(公告)日：2024-04-04
申请号：US18533611
申请日：2023-12-08
申请人： ONCOCLEW CO., LTD.
发明人： Se Jin JANG , Min Suh KIM , Young Ah SUH , Hye Min MUN , Ju Hee OH
IPC分类号： A61K49/00 , A01K67/027 , C12N5/09
CPC分类号： A61K49/0008 , A01K67/0271 , C12N5/0693 , A01K2207/12 , A01K2227/105 , A01K2267/0331 , C12N2500/38 , C12N2501/11 , C12N2501/113 , C12N2501/115 , C12N2501/727 , C12N2513/00 , C12N2533/50
摘要： The present invention relates to a method for culturing a 3-dimensional lung cancer organoid and a method for preparing a patient-derived xenograft animal model using the same. More specifically, the present invention relates to a method for culturing a 3-dimensional lung cancer organoid, a lung cancer organoid prepared by the method, a medium composition for culturing the lung cancer organoid, a method for preparing a xenograft animal model using the lung cancer organoid, a patient-derived lung cancer organoid xenograft animal model prepared by the method, and a method for analyzing therapeutic efficacy of an anticancer agent and a method for screening an anticancer agent, using the animal model.
-
公开(公告)号：US20240092857A1
公开(公告)日：2024-03-21
申请号：US18456339
申请日：2023-08-25
IPC分类号： C07K14/705 , C12N5/09
CPC分类号： C07K14/705 , C12N5/0694 , A61K38/00
摘要： Delta-like non-canonical Notch ligand 1 (DLK1) inhibitors are disclosed. The DLK1 inhibitors can be used to treat cancers such as myelodysplastic syndrome (MDS), and cancers of the liver, breast, brain, pancreas, colon, lung, kidney, ovary, testes, and/or adrenal gland, among other uses described herein.
-
公开(公告)号：US11921020B2
公开(公告)日：2024-03-05
申请号：US16939868
申请日：2020-07-27
IPC分类号： G01N1/40 , B01L3/00 , C12N5/09 , G01N33/487 , G01N33/50 , G01N33/574
CPC分类号： G01N1/40 , B01L3/502715 , B01L3/50273 , C12N5/0693 , G01N33/487 , G01N33/5026 , G01N33/5044 , G01N33/5091 , G01N33/574 , B01L2200/027 , B01L2200/0647 , B01L2400/0475 , C12N2521/00
摘要： Methods for isolating viable cancer cells from a sample that comprises a mixture of cancerous cells and normal (non-cancerous) cells are provided. In the methods, a fluid preparation comprising a mixture of cancerous and normal cells is repeatedly exposed to fluid shear stresses, whereby the repeated exposure to the fluid shear stresses preferentially imparts fluid shear stress-resistance to the cancerous cells.
-
29.发明授权公开(公告)号：US11920153B2
公开(公告)日：2024-03-05
申请号：US16339164
申请日：2017-10-03
发明人： Stefania Rapino , Francesco Zerbetto , Gastone Castellani , Stefano Salvioli , Beatrice Fraboni , Isabella Zironi , Maria Conte , Claudio Franceschi , Daniela Salvatore , Maila Becconi
IPC分类号： C12N5/00 , C12N5/09 , C12N9/00 , C12N9/02 , C12N9/04 , C12N9/08 , C12N11/04 , C12N11/06 , C12N11/087 , C12N11/089 , C12N11/12 , G01N33/50
CPC分类号： C12N5/0018 , C12N5/0068 , C12N5/0693 , C12N9/00 , C12N9/0006 , C12N9/0036 , C12N9/0053 , C12N9/0061 , C12N9/0065 , C12N9/0069 , C12N9/0093 , C12N11/04 , C12N11/06 , C12N11/087 , C12N11/089 , C12N11/12 , C12Y101/03004 , C12Y106/03001 , C12Y109/03001 , C12Y110/03002 , C12Y111/01006 , C12Y113/12004 , C12Y117/03002 , G01N33/5008 , C12N2500/02 , C12N2501/71 , C12N2533/30 , C12N2533/50 , C12N2533/54 , C12N2533/70 , C12N2533/72 , C12N2533/74 , C12N2533/76 , C12N2533/78 , C12N2533/80 , C12N2537/10
摘要： The present invention relates to compositions comprising a polymeric matrix or a gel containing functional enzymes capable of re-creating under culture conditions the cell microenvironment existing in vivo. The present invention also relates to devices for cell cultures comprising such compositions, in particular hydrogel and the use thereof to control the chemical microenvironment of a cell culture or mimic physiological or pathological conditions of the in vivo cells. The compositions and the devices described herein could be also used in vitro for evaluating the therapeutic effect of a compound on a determined cell line or on primary cells.
-
公开(公告)号：US11890303B2
公开(公告)日：2024-02-06
申请号：US17039671
申请日：2020-09-30
发明人： Matthias Stephan
CPC分类号： A61K35/17 , A01K67/0271 , A61K9/0024 , A61K9/146 , A61K39/44 , A61K45/06 , C07K16/2809 , C07K16/2818 , C07K16/2878 , C12N5/0694 , A01K2207/12 , A01K2227/105 , A01K2267/0331 , C12N2510/00 , C12N2533/54 , C12N2533/74
摘要： The present disclosure provides compositions and methods for the delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse. The compositions comprise (i) a structure comprising an injectable polymer or scaffold comprising pores; (ii) lymphocytes disposed within the structure, (iii) at least one lymphocyte-adhesion moiety associated with the structure; and (iv) at least one lymphocyte-activating moiety associated with the structure, and optionally an immune stimulant.
-
-
-
-
-
-
-
-
-
搜索结果
1918 条记录 (耗时 0.035 秒)
